Developer docs
API playgroundTry for free, no card

Search company profiles

Integra Holdings

Full company profile

uuid0002q1t

Namestring
Integra Holdings
Legal namestring
Integra Holdings
Company typeenum
Private
Founded yearint
2012
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersJerusalem, Israel
HQ citystring
Jerusalem
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital, biotech investments, life sciences holdings, academic technology transfer, pharmaceutical development
Industry1 code
PRIMARYFSAEAAAB
Investment Management Advisory (RIA)
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Biotech Venture Capital
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Returns
TypeLicensing Royalties
Description

Integra Holdings generates returns through equity investments in early-stage life science companies originating from Hebrew University research. They provide funding, strategic planning, business development and R&D guidance to portfolio companies, with returns realized through exits, licensing deals, or ongoing portfolio value.

integra-holdings.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Integra Holdings is a venture investment and biotech holding company that funds, guides, and commercializes early-stage life science innovations originating from Hebrew University of Jerusalem. It operates a portfolio of nine companies in therapeutic areas including oncology, neurology, respiratory, pain, infectious diseases, inflammation, and ophthalmology, providing equity capital, strategic planning, business development, and R&D guidance from inception through market entry.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Integra Holdings is a healthcare investment company that serves as an exclusive gateway for investment in Hebrew University life science early stage research and technologies. Rather than offering a unified product platform, Integra operates a diversified portfolio of 9 portfolio companies spanning Pharma Biotechnology, Medical devices, Diagnostics and AI. The portfolio includes: Ayana Pharma (FDA-approved liposomal cancer therapeutics); Nectin Therapeutics (immune oncology antibodies and ADCs); Splisense (RNA-based antisense oligonucleotide therapies for cystic fibrosis); HighRAD (medical imaging analysis platform); Neoprol (synthetic Propofol formulation); Lipocure (liposomal post-surgical pain treatments); OPhRx (ophthalmic drug delivery); RNAble (FTO inhibitor cancer therapeutics); and Lipomedix (targeted cancer prodrug). Each portfolio company operates independently with its own products, while Integra provides strategic guidance, funding, and commercialization support from inception to market.

Product and service9 records
1Ayana Pharma
CategoryPortfolio Company
Description

Portfolio company developing liposomal therapeutics for cancer treatment. Its FDA-approved product LC 101 (liposomal HCl-Doxorubicin) is used for treatment of ovarian cancer, multiple myeloma, and AIDS-related Kaposi's sarcoma, with strategic US marketing handled by Padagis (Perrigo).

2Nectin Therapeutics
CategoryPortfolio Company
Description

Portfolio company developing next-generation immune oncology therapies through novel monoclonal antibodies (mAbs) and antibody-drug-conjugates (ADCs) that target major escape mechanisms of current immuno-oncology therapies. Aimed at transforming outcomes for cancer patients.

3Splisense
CategoryPortfolio Company
Description

Clinical-stage portfolio company developing transformative RNA-based treatments using antisense oligonucleotides (ASOs) for pulmonary diseases including cystic fibrosis and idiopathic pulmonary fibrosis. Raised $28.5 million in Series B in 2021.

4HighRAD
CategoryPortfolio Company
Description

Portfolio company operating a quantitative platform for multi-organ tracking in longitudinal volumetric imaging studies (CT/MRI/PET), evaluating disease progression and treatment efficacy using its novel Region of Difference (ROD) technology.

5Neoprol
CategoryPortfolio Company
Description

Preclinical-stage portfolio company developing NP-09, an improved synthetic formulation of Propofol that addresses contamination risks associated with current animal and plant-derived Propofol products.

6Lipocure
CategoryPortfolio Company
Description

Preclinical-stage portfolio company developing novel liposomal drug candidates for post-surgical pain, including LC400, a novel liposomal hydrogel formulation of Bupivacaine.

7OPhRx
CategoryPortfolio Company
Description

Preclinical-stage portfolio company developing novel topical drug products for front-of-the-eye and back-of-the-eye diseases using lyotropic liquid crystals drug delivery technology. Lead candidates include OPH-101 for wet AMD and OPH-100 for Dry Eye Syndrome.

8RNAble
CategoryPortfolio Company
Description

Preclinical-stage portfolio company developing first-in-class small-molecule FTO inhibitors targeting cancers characterized by chromosomal instability (CIN). Lead candidate RNB-1720 exhibits oral bioavailability with confirmed efficacy across multiple CIN+ cancer models.

9Lipomedix
CategoryPortfolio Company
Description

Early-stage portfolio company developing Promitil-Pegylated Liposomal Mitomycin C Prodrug (PL-MLP), an innovative agent for targeted cancer therapy that overcomes MMC toxicity tolerability issues. Aimed at gastrointestinal-derived cancers including stomach, pancreatic, and colorectal.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-10-01
Description

LAB555 is the first academic BRIDGE Partnership in Israel, translating early-stage research from Hebrew University into industrial drug development. Leverages Integra's skill in identifying promising early-stage therapeutic projects, Yissum's translational expertise, and Evotec's industrial drug development platform.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Yissum is the technology transfer company of Hebrew University and Integra Holdings' founding parent. Yissum founded Integra Holdings in 2012 and provides exclusive access to Hebrew University's life science innovations. Yissum ranks among top technology transfer companies globally with over 8,900 patents and 2,500 inventions.

3Padagis (Perrigo)
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Ayana Pharma, an Integra portfolio company, has strategic agreement with Padagis for marketing of FDA-approved liposomal therapeutics in the US. Padagis was acquired by Altris for approximately $55.1 billion and has sales of hundreds of products in US and Israel.

integra-holdings.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Israeli life sciences and healthtech venture fund; led Nectin Therapeutics' Series B alongside Integra. Closely comparable in fund size, focus area, and Israeli biotech origination strategy.

TypeDirect peer
Description

Biotech-focused venture firm (GSK-affiliated) that has co-invested with Integra in portfolio companies such as Atox Bio. Comparable as a biotech-dedicated investor with similar therapeutic focus.

TypeDirect peer
Description

Israeli healthcare-dedicated venture firm co-investing with Integra across Hebrew University spin-outs (e.g., Avraham Pharmaceuticals). Operates with a similar thesis of bridging Israeli academic innovation to commercial biotech.

TypeDirect peer
Description

Healthcare/biotech investment arm of the Lundbeck Foundation; co-investor with Integra in Atox Bio. Comparable as a sector-focused, European-anchored biotech VC.

5Israel Biotech Fund (IBF)
TypeDirect peer
Description

Specialist Israeli biotech venture investor participating alongside Integra in rounds like Splisense. Directly comparable as a sector-focused Israeli biotech VC.

TypeDirect peer
Description

Israeli arm of the global OrbiMed healthcare investment platform; co-invested with Integra in Splisense and Atox Bio. Comparable as a biotech-dedicated VC investing in Israeli innovation.

TypeBroad incumbent
Description

Global corporate venture arm of J&J with deep biotech and academic spin-out activity. Comparable at a thematic level as a large-scale investor in early-stage biotech innovation arising from academic research, though with vastly broader scope and capital base.

TypeDirect peer
Description

Israeli life sciences investment company that jointly established OPhRx with Integra. Comparable as a portfolio-style Israeli life sciences holding/investment company.

TypeDirect peer
Description

Israeli biotech holding company co-investing with Integra in Avraham Pharmaceuticals. Comparable structure as a publicly-affiliated biotech investment vehicle operating in the Israeli ecosystem.

TypeBroad incumbent
Description

Hebrew University's technology transfer company and Integra's founding parent. Comparable as a broader tech transfer and commercialization vehicle, but with much wider scope beyond life sciences and beyond pure venture investing.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries9 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment8 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Integra Holdings

Biotech Venture Capitalintegra-holdings.com

Integra Holdings firmographics

Firmographics
Name
Integra Holdings
Legal name
Integra Holdings
Website
https://integra-holdings.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Integra Holdings industry classification

Industry
Product category
Biotech Venture Capital
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSAEAAAB
Investment Management Advisory (RIA)

Keywords

  • Venture capital
  • Biotech investments
  • Life sciences holdings
  • Academic technology transfer
  • Pharmaceutical development

Where Integra Holdings is headquartered

Location

Headquarters

HQ city
Jerusalem
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Integra Holdings business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Others

Revenue model

  1. Investment Returns: Integra Holdings generates returns through equity investments in early-stage life science companies originating from Hebrew University research. They provide funding, strategic planning, business development and R&D guidance to portfolio companies, with returns realized through exits, licensing deals, or ongoing portfolio value.

Go-to-market motion1 record

Marketing channels3 records

Integra Holdings product offering

Product offering

Core offering

Integra Holdings is a venture investment and biotech holding company that funds, guides, and commercializes early-stage life science innovations originating from Hebrew University of Jerusalem. It operates a portfolio of nine companies in therapeutic areas including oncology, neurology, respiratory, pain, infectious diseases, inflammation, and ophthalmology, providing equity capital, strategic planning, business development, and R&D guidance from inception through market entry.

Product overview

Integra Holdings is a healthcare investment company that serves as an exclusive gateway for investment in Hebrew University life science early stage research and technologies. Rather than offering a unified product platform, Integra operates a diversified portfolio of 9 portfolio companies spanning Pharma Biotechnology, Medical devices, Diagnostics and AI. The portfolio includes: Ayana Pharma (FDA-approved liposomal cancer therapeutics); Nectin Therapeutics (immune oncology antibodies and ADCs); Splisense (RNA-based antisense oligonucleotide therapies for cystic fibrosis); HighRAD (medical imaging analysis platform); Neoprol (synthetic Propofol formulation); Lipocure (liposomal post-surgical pain treatments); OPhRx (ophthalmic drug delivery); RNAble (FTO inhibitor cancer therapeutics); and Lipomedix (targeted cancer prodrug). Each portfolio company operates independently with its own products, while Integra provides strategic guidance, funding, and commercialization support from inception to market.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ayana Pharma Portfolio company developing liposomal therapeutics for cancer treatment. Its FDA-approved product LC 101 (liposomal HCl-Doxorubicin) is used for treatment of ovarian cancer, multiple myeloma, and AIDS-related Kaposi's sarcoma, with strategic US marketing handled by Padagis (Perrigo).
  • Nectin Therapeutics Portfolio company developing next-generation immune oncology therapies through novel monoclonal antibodies (mAbs) and antibody-drug-conjugates (ADCs) that target major escape mechanisms of current immuno-oncology therapies. Aimed at transforming outcomes for cancer patients.
  • Splisense Clinical-stage portfolio company developing transformative RNA-based treatments using antisense oligonucleotides (ASOs) for pulmonary diseases including cystic fibrosis and idiopathic pulmonary fibrosis. Raised $28.5 million in Series B in 2021.
  • HighRAD Portfolio company operating a quantitative platform for multi-organ tracking in longitudinal volumetric imaging studies (CT/MRI/PET), evaluating disease progression and treatment efficacy using its novel Region of Difference (ROD) technology.
  • Neoprol Preclinical-stage portfolio company developing NP-09, an improved synthetic formulation of Propofol that addresses contamination risks associated with current animal and plant-derived Propofol products.
  • Lipocure Preclinical-stage portfolio company developing novel liposomal drug candidates for post-surgical pain, including LC400, a novel liposomal hydrogel formulation of Bupivacaine.
  • OPhRx Preclinical-stage portfolio company developing novel topical drug products for front-of-the-eye and back-of-the-eye diseases using lyotropic liquid crystals drug delivery technology. Lead candidates include OPH-101 for wet AMD and OPH-100 for Dry Eye Syndrome.
  • RNAble Preclinical-stage portfolio company developing first-in-class small-molecule FTO inhibitors targeting cancers characterized by chromosomal instability (CIN). Lead candidate RNB-1720 exhibits oral bioavailability with confirmed efficacy across multiple CIN+ cancer models.
  • Lipomedix Early-stage portfolio company developing Promitil-Pegylated Liposomal Mitomycin C Prodrug (PL-MLP), an innovative agent for targeted cancer therapy that overcomes MMC toxicity tolerability issues. Aimed at gastrointestinal-derived cancers including stomach, pancreatic, and colorectal.

Companies that use Integra Holdings

Customer profile

Segments1 record

Ideal customer profiles3 records

Integra Holdings technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integra Holdings partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and major.

  • EvoteccoreStrategic or Co-development Partner · 1 October 2019LAB555 is the first academic BRIDGE Partnership in Israel, translating early-stage research from Hebrew University into industrial drug development. Leverages Integra's skill in identifying promising early-stage therapeutic projects, Yissum's translational expertise, and Evotec's industrial drug development platform.
  • YissumcoreStrategic or Co-development PartnerYissum is the technology transfer company of Hebrew University and Integra Holdings' founding parent. Yissum founded Integra Holdings in 2012 and provides exclusive access to Hebrew University's life science innovations. Yissum ranks among top technology transfer companies globally with over 8,900 patents and 2,500 inventions.
  • Padagis (Perrigo)majorChannel Partner/ Reseller/ DistributorAyana Pharma, an Integra portfolio company, has strategic agreement with Padagis for marketing of FDA-approved liposomal therapeutics in the US. Padagis was acquired by Altris for approximately $55.1 billion and has sales of hundreds of products in US and Israel.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Integra Holdings competitors and assessment

Company assessment

Direct peers

  • aMoon Fund: Israeli life sciences and healthtech venture fund; led Nectin Therapeutics' Series B alongside Integra. Closely comparable in fund size, focus area, and Israeli biotech origination strategy.
  • SR One: Biotech-focused venture firm (GSK-affiliated) that has co-invested with Integra in portfolio companies such as Atox Bio. Comparable as a biotech-dedicated investor with similar therapeutic focus.
  • Pontifax: Israeli healthcare-dedicated venture firm co-investing with Integra across Hebrew University spin-outs (e.g., Avraham Pharmaceuticals). Operates with a similar thesis of bridging Israeli academic innovation to commercial biotech.
  • Lundbeckfond Ventures: Healthcare/biotech investment arm of the Lundbeck Foundation; co-investor with Integra in Atox Bio. Comparable as a sector-focused, European-anchored biotech VC.
  • Israel Biotech Fund (IBF): Specialist Israeli biotech venture investor participating alongside Integra in rounds like Splisense. Directly comparable as a sector-focused Israeli biotech VC.
  • OrbiMed Israel: Israeli arm of the global OrbiMed healthcare investment platform; co-invested with Integra in Splisense and Atox Bio. Comparable as a biotech-dedicated VC investing in Israeli innovation.
  • BioLight Life Sciences Investments: Israeli life sciences investment company that jointly established OPhRx with Integra. Comparable as a portfolio-style Israeli life sciences holding/investment company.
  • Clal Biotechnology Industries (CBI): Israeli biotech holding company co-investing with Integra in Avraham Pharmaceuticals. Comparable structure as a publicly-affiliated biotech investment vehicle operating in the Israeli ecosystem.

Broad incumbents

  • Johnson & Johnson Innovation (JJDC): Global corporate venture arm of J&J with deep biotech and academic spin-out activity. Comparable at a thematic level as a large-scale investor in early-stage biotech innovation arising from academic research, though with vastly broader scope and capital base.
  • Yissum Research Development Company: Hebrew University's technology transfer company and Integra's founding parent. Comparable as a broader tech transfer and commercialization vehicle, but with much wider scope beyond life sciences and beyond pure venture investing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Integra Holdings financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Integra Holdings leadership team

Management profile

Number of profiles

Profiles3 records

Integra Holdings subsidiaries and ownership

Company hierarchy

Subsidiaries9 records

Integra Holdings funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Integra Holdings M&A and investment

M&A and investment

M&A

Investments8 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Integra Holdings

What does Integra Holdings do?

Integra Holdings is a venture investment and biotech holding company that funds, guides, and commercializes early-stage life science innovations originating from Hebrew University of Jerusalem. It operates a portfolio of nine companies in therapeutic areas including oncology, neurology, respiratory, pain, infectious diseases, inflammation, and ophthalmology, providing equity capital, strategic planning, business development, and R&D guidance from inception through market entry.

Is Integra Holdings a public or private company?

Integra Holdings is a private company. It is classified as venture growth investor backed and is currently operating.

When was Integra Holdings founded?

Integra Holdings was founded in 2012. It employs 1 to 10 people.

Where is Integra Holdings based?

Integra Holdings is headquartered in Jerusalem, Israel, in the Middle East region.

How does Integra Holdings make money?

One revenue line is on record: investment Returns.

Who are Integra Holdings's main competitors?

Direct peers on record are aMoon Fund, SR One, Pontifax, Lundbeckfond Ventures, Israel Biotech Fund (IBF), OrbiMed Israel, BioLight Life Sciences Investments and Clal Biotechnology Industries (CBI). Broad incumbents are Johnson & Johnson Innovation (JJDC) and Yissum Research Development Company.

Does Integra Holdings have an API?

No public API is recorded for Integra Holdings.

What industry is Integra Holdings in?

Integra Holdings's product category is Biotech Venture Capital. Its primary akta.pro industry code is FSAEAAAB, Investment Management Advisory (RIA). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
IFTTTIsraeli immuno-oncology co Nectin raises $6mNectin Therapeutics completed a $6 million financing round led by aMoon Velocity, with Integra Holdings participating. The company plans to raise $15 million total to develop monoclonal antibodies targeting the Nectin family of proteins. The antibodies aim to boost the immune system's ability to fight cancers.The Pharma LetterBRIEF—Evotec launches new collaboration in IsraelEvotec launched a collaboration with Israeli investors Integra Holdings and Yissum, the Hebrew University's technology transfer company. The deal, part of Evotec's BRIDGE public-private partnerships, aims to combine academia, biotech, and venture capital. CEO Werner Lanthaler said the partnership will accelerate next-generation drug development.FinSMEsIntegra Holdings Recieves $25m Investment Led by TemasaekIntegra Holdings, a Jerusalem-based life science investment company, closed a $25M funding round led by Temasek with $15M, with participation from Arie Capital and the Israeli Teachers' and Kindergarten's Study Funds. The funds will advance existing portfolio companies and create new ones based on Hebrew University life science technologies.PR NewswireTemasek Leads $25 Million Investment Round in Integra HoldingsTemasek led a $25 million investment round in Integra Holdings, contributing $15 million alongside Arie Capital and existing shareholder The Israeli Teachers' and Kindergarten's Study Funds. The capital will be used to advance Integra's existing portfolio companies and create new ventures based on life science innovations from the Hebrew University of Jerusalem.PR NewswireTemasek dirige un cycle d'investissement de 25 millions USD dans Integra HoldingsTemasek led a $25 million investment round in Integra Holdings, contributing $15 million alongside Arie Capital and existing shareholders. The funds will be used to expand Integra's portfolio of life sciences innovations derived from the Hebrew University of Jerusalem and to commercialize new technologies.PR NewswireTemasek lidera una ronda de inversión de 25 millones de dólares en Integra HoldingsIntegra Holdings announced the first closing of a $25 million investment round, led by Temasek with a $15 million contribution alongside Arie Capital's $2 million initial investment and participation from The Israeli Teachers' and Kindergarten's Study Funds. The funds will be used to advance Integra Holdings' existing portfolio companies and create new ventures based on technologies from the Hebrew University of Jerusalem. Temasek, a Singapore-based investment company with a net portfolio value of $197 billion, cited the opportunity to help promising discoveries reach their full potential through a broader network of entrepreneurs, investors, and industry partners.PR NewswireTemasek führt Beteiligungsrunde über 25 Millionen US$ an Integra HoldingsIntegra Holdings announced a $25 million funding round led by Temasek, with Arie Capital and the Israeli Teachers' and Kindergarten's Study Funds participating. The funds will support expansion of its portfolio and new ventures based on Hebrew University's life science innovations.PR NewswireTemasek führt Beteiligungsrunde über 25 Millionen US$ an Integra HoldingsIntegra Holdings, a venture organization focused on life science innovations from the Hebrew University of Jerusalem, announced the first closing of a $25 million investment round, led by Temasek with a $15 million contribution alongside Arie Capital's $2 million participation. The Israeli Teachers' and Kindergarten's Study Funds, an existing shareholder, also participated in the round. The funds will be used to develop Integra Holdings' existing portfolio companies and to establish new companies based on promising technologies from the Hebrew University.GlobesLife science investment co Integra raises $25mIntegra Holdings, a life science investment fund, closed a $25 million financing round led by Temasek, with Arie Capital and the Israeli Teachers' and Kindergartens' Study Funds participating. The round brings total funding to $40 million over five years, to advance portfolio companies and new ventures. Two portfolio companies, Ayana Pharma and Atox Bio, are at advanced stages.The Jerusalem PostHebrew U student develops breakthrough in Parkinson’s diagnosis.Suaad Abd Elhadi, a Hebrew University doctoral student, developed a lipid ELISA assay to detect Parkinson's disease biomarkers, earning a 2017 Kaye Innovation Award. The tool could enable earlier diagnosis and better treatment tracking, with Yissum holding patents and an agreement with Integra Holdings for commercialization.